*Vascular Medicine Outcomes (VAMOS) Program, Department of Internal Medicine, Cardiovascular Medicine Section, Yale School of Medicine, New Haven, CT
†Department of Psychiatry, Yale School of Medicine, New Haven, CT
‡Optum Care, Eden Prairie, MN
§Optum Labs, Minnetonka, MN
This study was supported by UnitedHealthcare, Medicare & Retirement. K.G.S. reports unrestricted research grants from Philips, Merck, Shockwave, and Johnson & Johnson; C.M.-H. reports unrestricted research grants from Philips and Shockwave.
K.G.S. is a Haemonetics consultant for Optum Labs, Cook, Tegus, Twill Inc., and Abbott. C.M.-H. is a Haemonetics consultant for Abbott Vascular, Boston Scientific, Cook, Medtronic, Cardinal Health, and Optum Labs. K.H. and O.A. are employees of Optum Care. The remaining authors declare no conflict of interest.
Correspondence to: Kim G. Smolderen, PhD, Department of Internal Medicine, Section of Cardiovascular Medicine, 789 Howard Avenue, New Haven, CT 06519. E-mail: [email protected].
Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.lww-medicalcare.com.